Modality
Fusion Protein
MOA
GLP-1/GIP
Target
GLP-1R
Pathway
Neuroinflam
RSVPV
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
~Mar 2019
→ ~Jun 2020
NDA/BLA
~Sep 2020
→ ~Dec 2021
Approved
Mar 2022
→ Nov 2029
ApprovedCurrent
NCT06984051
838 pts·PV
2024-06→2026-10·Active
NCT05454960
1,675 pts·PV
2024-08→2029-11·Completed
NCT06501995
2,157 pts·PV
2022-03→2027-01·Active
4,670 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-10-076mo awayPh3 Readout· PV
2027-01-099mo awayPh3 Readout· PV
2029-11-093.6y awayPh3 Readout· PV
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Active
Approved
Active
Approved
Complet…
Catalysts
Ph3 Readout
2026-10-07 · 6mo away
PV
Ph3 Readout
2027-01-09 · 9mo away
PV
Ph3 Readout
2029-11-09 · 3.6y away
PV
ActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06984051 | Approved | PV | Active | 838 | PANSS |
| NCT05454960 | Approved | PV | Completed | 1675 | VA |
| NCT06501995 | Approved | PV | Active | 2157 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |